Medicines Updates and Statements

10.13.2023

Pfizer’s ELREXFIO™ Receives Positive CHMP Opinion for Relapsed and Refractory Multiple Myeloma

10.05.2023

FDA Grants Interchangeable Designation to Pfizer’s Biosimilar ABRILADA™

10.02.2023

Hospira, Inc. Issues A Voluntary Nationwide Recall For 4.2% Sodium Bicarbonate Injection, USP and 1% and 2% Lidocaine HCl Injection, USP Due To The Potential For Presence of Glass Particulate Matter

07.21.2023

Pfizer Receives Positive CHMP Opinion for Alopecia Areata Treatment

06.05.2023

Pfizer Announces DUAVEE® (conjugated estrogens/bazedoxifene), an Estrogen-Based Menopause Hormone Therapy, Now Back in Stock with Improved Packaging

01.30.2023

Pfizer and International Trachoma Initiative Deliver One Billionth Zithromax® Dose Toward Trachoma Elimination by 2030

01.27.2023

Pfizer Receives Positive CHMP Opinion for Conversion of PAXLOVID™ Conditional Marketing Authorization to Full Marketing Authorization in the European Union

12.22.2022

Hospira, Inc. Issues A Voluntary Nationwide Recall For One Lot of Vancomycin Hydrochloride Injection, USP 1.5g/vial, Due To The Presence of Visible Glass Particulates

12.20.2022

U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™

12.13.2022

Pfizer to Provide U.S. Government with an Additional 3.7 Million Treatment Courses of PAXLOVID™ to Help Combat COVID-19

11.23.2022

Pfizer Signs Agreement to Provide the European Union with PAXLOVID™

10.28.2022

Safety Recommendation on Janus kinase (JAK) Inhibitors Issued in the European Union